Antithrombotic therapy in hypertension: A cochrane systematic review

Journal of Human Hypertension

Volumn 19, Issue 3, 2005, Pages 185-196

  Felmeden, D C ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Antithrombotic therapy; Aspirin; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; FELODIPINE; FIBRINOGEN RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TICLOPIDINE; WARFARIN;

ARTERY DISEASE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG FATALITY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS;

ASPIRIN; BLOOD PRESSURE; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; MIDDLE AGED; THROMBOSIS; WARFARIN;

EID: 14944356764     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001807     Document Type: Review

References (98)

1. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272-298.
2. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
3. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
5. Lip GYH, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? J Intern Med 2001; 249: 205-214.
6. Lip GYH, Beevers DG. Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8: 693-702.
7. Lee AJ. The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 1997; 11: 767-776.
8. Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens Suppl 1996; 14: S83-S93.
9. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000; 101: 218-220.
10. Lip GYH et al. Relationship of endothelium, thrombogenesis, and haemorrheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566-1571.
11. Segal JB et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: Cochrane Library, Issue 2. Update Software: Oxford, 2001 CD001938.
12. SPAF II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
13. Lip GYH, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm (Cochrane Review). In: The Cochrane Library, Issue 4. John Wiley & Sons, Ltd: Chichester, UK, 2001 CD003333.
14. WHO-ISHGMH. World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-183.
15. Ramsay L et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
16. WHO Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-918.
17. Clarke M, Oxman AD (eds). Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
18. Mulrow CD, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997; 126 389-391.
19. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13-17.
20. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-241.
21. O'Connor CM et al. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). Am J Cardiol 2001; 88: 541-546.
22. Mohr JP et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-1451.
23. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857-865.
24. Huynh T et al. Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 3069-3074.
25. Schuhlen H et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001; 37: 2066-2073.
26. Thel MC et al. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. Am Heart J 1999; 137: 264-273.
27. Kleiman NS et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998; 97 1912-1920.
28. Novo S et al. Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. Int Angiol 1996; 15: 169-174.
29. Finelli C et al. Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A double-blind controlled study. Acta Haematol 1991; 85 113-118.
30. Hass WK, et al., for the Ticlopidine Aspirin Stroke Study Group. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507.
31. Hansson L, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment randomised trial. Lancet 1998; 351: 1755-1762.
32. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
33. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
34. O'Neill WW et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N Engl J Med 2000; 342: 1316-1324.
35. Dickersin K, Herxheimer A. Introduction: the quality of the medical evidence: is it good enough? Int J Technol Assess Health Care 1996; 12: 187-189.
36. Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Paper presented at the Fourth International Cochrane Colloquium, Adelaide, Australia, 20-24 October 1996.
37. Ajani UA et al. Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 2000; 102 500-505.
38. Bhatt DL et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000; 140: 67-73.
39. Bhatt DL et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103: 363-368.
40. Califf RM et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101: 2231-2238.
41. Caravaca F et al. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrol Dial Transplant 1995; 10: 1720-1724.
42. Cook ME et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997; 24 1137-1144.
43. Cusson JR et al. Effect of ketoprofen on blood pressure, endocrine and renal responses to chronic dosing with captopril in patients with essential hypertension. Blood Press 1992; 1: 162-167.
44. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA 1972; 222: 541-548.
45. Forbes CD, for the ESPS Investigators. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamol alone and in combination. Thromb Res 1998; 92: S1-S6.
46. Ferri C et al. Enhanced blood pressure response to cyclooxygenase inhibition in salt-sensitive human essential hypertension. Hypertension 1993; 21(6 Part 1): 875-881.
47. Fisher LD, Gent M, Buller HR. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001; 141: 26-32.
48. Forbes CD et al. Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist. Semin Thromb Hemost 1999; 25: 55-60.
49. Furey SA, Vargas R, McMahon FG. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13: 143-148.
50. Gurwitz JH et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996; 51: M74-M79.
51. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999; 21: 325-335.
52. Harpaz D et al. Effect of aspirin on the mortality in women with symptomatic or silent myocardial infarction. Am J Cardiol 1996; 78: 1215-1219.
53. Hartmann D et al. Study on the possible interaction between tenoxicam and atenolol in hypertensive patients. Arzneimittelforschung 1995; 45: 494-498.
54. Harvey PJ et al. Effect of indomethacin on blood pressure control during treatment with nitrendipine. Blood Press 1995; 4: 307-312.
55. Hermida RC et al. Influence of aspirin usage on blood pressure: dose and administration-time dependencies. Chronobiol Int 1997; 14: 619-637.
56. Herskovits E et al. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol 1985; 24: 73-81.
57. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415-419.
58. Houston MC et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155: 1049-1054.
59. Houtsmuller AJ et al. The influence of teiclopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984; 15: 219-229.
60. Johnson AG et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens 1996; 10: 257-261.
61. Klassen D et al. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. J Clin Pharmacol 1993; 33: 971-978.
62. Klassen DK, Jane LH, Young DY, Peterson CA. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 1995; 8: 146-153.
63. Lee IM et al. Exercise and risk of stroke in male physicians. Stroke 1999; 30: 1-6.
64. Lemak NA, Fields WS, Gary Jr HE. Controlled trial of aspirin in cerebral ischemia: an addendum. Neurology 1986; 36: 705-710.
65. Magagna A et al. Indomethacin raises blood pressure in untreated essential hypertensives: a double-blind randomly allocated study versus placebo. J Hypertens Suppl 1991; 9: S242-S243.
66. Magagna A et al. Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients. Blood Press 1994; 3: 236-241.
67. Maggioni AP et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. N Engl J Med 1992; 327: 1-6.
68. Mehta SR et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
69. Mills EH, Whitworth JA, Andrews J, Kincaid-Smith P. Non-steroidal anti-inflammatory drugs and blood pressure. Aust N Z J Med 1982; 12: 478-482.
70. Minuz P, Barrow SE, Cockcroft JR, Ritter JM. Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension. Br J Clin Pharmacol 1990; 30: 519-526.
71. Minuz P et al. Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition. Br J Clin Pharmacol 1995; 39: 45-50.
72. Morgan T, Anderson A. Interaction of indomethacin with felodipine and enalapril. J Hypertens Suppl 1993; 11(Suppl 5): S338-S339.
73. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000; 13 1161-1167.
74. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999; 12(8 Part 1): 784-789.
75. Oosterga M et al. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998; 81: 1178-1181.
76. Pancera P et al. Changes in peripheral hemodynamics and vasodilating prostaglandins after high-dose short-term ibuprofen in chronically treated hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 217-222.
77. Peto R et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-316.
78. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
79. Polonia J et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995; 13: 925-931.
80. Polonia J, Gama G, Santos A. [Reduction of the antihypertensive effects of enalapril by indomethacin. Its independence from renal sodium retention]. Rev Port Cardiol 1996; 15: 460, 485-492.
81. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89-95.
82. Pritchard G et al. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Br J Clin Pharmacol 1997; 44: 145-149.
83. Proudman SM et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intra-articular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809-1819.
84. Puranen J, Laakso M, Riekkinen Sr PJ, Sivenius J. Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke. J Cardiovasc Pharmacol 1998; 32: 291-294.
85. Mahaffey KW et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999; 99: 2371-2377.
86. Saloheimo P, Juvela S, Hillborn M. Use of aspirin, epistaxis and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke 2001; 32 399-404.
87. Schreiber TL et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992; 86: 1407-1414.
88. Sivenius J et al. Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. Arch Neurol 1993; 50: 710-713.
89. Smith SR, Coffman TM, Svetkey LP. Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol 1993; 4: 1133-1139.
90. Sturrock ND, Lang CC, Struthers AD. Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertens 1994; 12: 919-924.
91. Takeuchi K et al. No adverse effect of non-steroidal anti-inflammatory drugs, sulindac and diclofenac sodium, on blood pressure control with a calcium antagonist, nifedipine, in elderly hypertensive patients. Tohoku J Exp Med 1991; 165: 201-208.
92. Thakur V, Cook ME, Wallin JD. Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal anti-inflammatory drugs. Am J Hypertens 1999; 12 9 Part 1): 925-928.
93. Tison P et al. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin. Blood Press Suppl 1994; 1: 57-60.
94. Tsuji T, Yasu T, Katayama Y, Imanishi M. Different patterns of renal prostaglandins 12 and E2 in patients with essential hypertension with low to normal or high renin activity. J Hypertens 2000; 18 1091-1096.
95. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054.
96. Walter E, Kaufmann W, Oster P. Does chronic aspirin treatment increase blood pressure in man? Klin Wochenschr 1981; 59: 297-299.
97. Whelton A et al. Cyclooxygenase-2 - specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85-95.
98. Celis H et al. Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-based antihypertensive treatment in the Syst-Eur trial. J Hum Hypertens 2001; 15: 613-618.